These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22951787)

  • 21. AAN Updates Guidelines on the Uses of Botulinum Neurotoxin.
    Wilkes J
    Am Fam Physician; 2017 Feb; 95(3):198-199. PubMed ID: 28145664
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.
    Hassell TJW; Charles D
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32331272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Botulinum toxin A in therapy of craniocervical dystonias and hemifacial spasm].
    Thill R; Költringer P; Reisecker F; Maller J; Leblhuber F
    Acta Med Austriaca; 1991; 18(5):125-9. PubMed ID: 1796725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin in the treatment of neurological disorders.
    Denislic M; Pirtosek Z; Vodusek DB; Zidar J; Meh D
    Ann N Y Acad Sci; 1994 Mar; 710():76-87. PubMed ID: 8154763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome.
    Dressler D; Wittstock M; Benecke R
    Eur Neurol; 2001; 45(4):287-8. PubMed ID: 11385272
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experience with botulinum toxin treatment of facial-cervical dystonias and hemifacial spasm].
    Erbguth F; Claus D; Neundörfer B
    Nervenarzt; 1990 Oct; 61(10):611-4. PubMed ID: 2274093
    [No Abstract]   [Full Text] [Related]  

  • 27. Botulinum toxin in the treatment of dystonias--a hospital based study.
    Gupta M; Singh G; Khwaja G
    J Assoc Physicians India; 2003 May; 51():447-53. PubMed ID: 12974424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and treatment of abductor hallucis focal dystonia with botulinum toxin injection: a case presentation.
    Rosenberg NS; Odderson IR
    PM R; 2013 Aug; 5(8):726-8. PubMed ID: 23953019
    [No Abstract]   [Full Text] [Related]  

  • 29. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54(5):210-7. PubMed ID: 1804035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54 Suppl 3():44-51. PubMed ID: 1810208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is new in the era of focal dystonia treatment? Botulinum injections and more.
    Cetinkaya A; Brannan PA
    Curr Opin Ophthalmol; 2007 Sep; 18(5):424-9. PubMed ID: 17700237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The use of botulinum toxin in ophthalmology].
    Lanzl I; Roggenkämper P; Merté RL
    Klin Monbl Augenheilkd; 2014 Jul; 231(7):749-63. PubMed ID: 25036810
    [No Abstract]   [Full Text] [Related]  

  • 33. [Botulinum toxin therapy: from dreaded biological toxin to standard pharmaceutical].
    Schnider P; Voller B; Moraru K; Auff E
    Wien Klin Wochenschr; 1999 Oct; 111(20):825-9. PubMed ID: 10586486
    [No Abstract]   [Full Text] [Related]  

  • 34. [Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study].
    Echeverría Urabayen A; Fanjul S; Meseguer E; García Ruiz Espiga PJ
    Rev Neurol; 2004 Mar 16-31; 38(6):511-3. PubMed ID: 15054712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical symptoms, diagnosis and treatment of focal dystonias].
    Klivényi P; Vécsei L
    Orv Hetil; 2001 Oct; 142(42):2293-7. PubMed ID: 11760645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Botulin A toxin: a highly effective drug in the treatment of focal dystonia].
    Timerbaeva SL; Ivanova-Smolenskaia IA; Markova ED; Poleshchuk VV; Karapetian MV; Rebrova OIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(5):32-5. PubMed ID: 10849964
    [No Abstract]   [Full Text] [Related]  

  • 37. [Use of botulinum toxin type A in neuro-ORL].
    Périé S; Lacau St Guily J
    Ann Readapt Med Phys; 2003 Jul; 46(6):375-9. PubMed ID: 12928145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dystonia, botulinum neurotoxin, and the aviator.
    Feinberg MJ
    Aviat Space Environ Med; 1999 Dec; 70(12):1235-7. PubMed ID: 10596783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Riolan's muscle: action and indications for botulinum toxin injection.
    Mackie IA
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.